Home › Funds › ARMISTICE CAPITAL, LLC › PTCT

ARMISTICE CAPITAL, LLC position in PTCT

PTC THERAPEUTICS INC · Health Care

ARMISTICE CAPITAL, LLC reported holding 660,000 shares of PTCT (PTC THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$53.8M, representing 0.71% of its reported portfolio and ranking #18 among its reported holdings. ARMISTICE CAPITAL, LLC has disclosed PTCT holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)660.00K sh
Reported value held$53.84M
Portfolio Weight0.71%
First reportedQ3 2023
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How ARMISTICE CAPITAL, LLC's PTCT position evolved

ARMISTICE CAPITAL, LLC first disclosed a stake in PTCT in Q3 2023 at 6,150,000 shares (US$137.8M). The position peaked in Q4 2024 at 6,378,000 shares, worth US$287.9M. Across 12 filings, ARMISTICE CAPITAL, LLC increased the stake 4 time(s), trimmed it 7 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 660,000 shares valued at US$53.8M — an increase of 270,000 shares quarter over quarter.. Notable position changes include a 31% trim in Q3 2025 (shares rose 24% over the following quarter), a 86% trim in Q1 2026 (shares rose 20% over the following quarter), a 69% increase in Q2 2026 (shares fell 21% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 6.15M $137.82M New
Q4 2023 6.86M $189.17M Add
Q1 2024 6.76M $196.76M Reduce
Q2 2024 6.96M $212.90M Add
Q3 2024 7.23M $268.41M Add
Q4 2024 6.38M $287.90M Reduce
Q1 2025 5.43M $276.96M Reduce
Q2 2025 4.74M $231.28M Reduce
Q3 2025 3.28M $201.13M Reduce
Q4 2025 2.80M $212.83M Reduce
Q1 2026 390.00K $26.57M Reduce
Q2 2026 660.00K $53.84M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About PTCT and 13F data

PTCT (PTC THERAPEUTICS INC) is a Health Care company. 54 other funds we track also report a position in PTCT — the largest reported positions include RTW INVESTMENTS, LP (US$631.9M), TORONTO DOMINION BANK (US$176.7M), WESTFIELD CAPITAL MANAGEMENT CO LP (US$159.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding PTCT

All PTCT fund holders →

FAQ

How long has ARMISTICE CAPITAL, LLC held PTCT?

ARMISTICE CAPITAL, LLC has disclosed PTCT holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is ARMISTICE CAPITAL, LLC's current position in PTCT?

As of Q2 2026, ARMISTICE CAPITAL, LLC holds 660.00K shares of PTCT (PTC THERAPEUTICS INC), valued at $53.84M, representing 0.71% of its reported portfolio and ranking #18.

Has ARMISTICE CAPITAL, LLC been buying or selling PTCT?

In the latest 13F filing (Q2 2026), ARMISTICE CAPITAL, LLC increased its position in PTCT. The position peaked in Q4 2024 at 6.38M shares.

Which other funds hold PTCT?

Other major institutional holders of PTCT include RTW INVESTMENTS, LP, TORONTO DOMINION BANK, WESTFIELD CAPITAL MANAGEMENT CO LP, among 54 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.